Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.

References

• Riordan JR, Rommens JM, Kerem B-S, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–1073.
   PubMed Web of Science ®Google Scholar
• Stephenson AL, Sykes J, Stanojevic S, et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017 Apr 18;166(8):537–546. PubMed PMID: 28288488; PubMed Central PMCID: PMCPMC5467971.
   PubMed Web of Science ®Google Scholar
• Pettit RS. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment [Review]. Ann Pharmacother. 2012 Jul-Aug;46(7–8):1065–1075. PubMed PMID: 22739718.
   PubMed Web of Science ®Google Scholar
• Anonymous. Canadian cystic fibrosis registry. Toronto; 2013.
   Google Scholar
• Kim SJ, Skach WR. Mechanisms of CFTR folding at the endoplasmic reticulum. Front Pharmacol. 2012;3:201. PubMed PMID: 23248597; PubMed Central PMCID: PMC3521238.
   PubMed Web of Science ®Google Scholar
• Braakman I, Hebert DN. Protein folding in the endoplasmic reticulum [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. Review]. Cold Spring Harb Perspect Biol. 2013 May 01;5(5):a013201. PubMed PMID: 23637286; PubMed Central PMCID: PMC3632058.
   PubMed Web of Science ®Google Scholar
• Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis [Review]. Nature. 2011 Jul 20;475(7356):324–332. PubMed PMID: 21776078.
   PubMed Web of Science ®Google Scholar
• Anelli T, Sitia R. Protein quality control in the early secretory pathway [Research Support, Non-U.S. Gov’t Review]. Embo J. 2008 Jan 23;27(2):315–327. PubMed PMID: 18216874; PubMed Central PMCID: PMC2234347.
   PubMed Web of Science ®Google Scholar
• Jensen TJ, Loo MA, Pind S, et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell. 1995;83:129–135.
   PubMed Web of Science ®Google Scholar
• Ward C, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell. 1995;83:121–127.
   PubMed Web of Science ®Google Scholar
• Pranke IM, Sermet-Gaudelus I. Biosynthesis of cystic fibrosis transmembrane conductance regulator. Int J Biochem Cell Biol. 2014 Jul;52:26–38. PubMed PMID: 24685677.
   PubMed Web of Science ®Google Scholar
• Farinha CM, Matos P, Amaral MD. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. Febs J. 2013 Sep;280(18):4396–4406. PubMed PMID: 23773658.
   PubMed Web of Science ®Google Scholar
• Hudock KM, Clancy JP. An update on new and emerging therapies for cystic fibrosis. Expert Opin Emerg Drugs. 2017 Dec;22(4):331–346. PubMed PMID: 29264936.
   PubMed Web of Science ®Google Scholar
• Maiuri L, Raia V, Kroemer G. Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ. 2017 Nov;24(11):1825–1844. PubMed PMID: 28937684; PubMed Central PMCID: PMCPMC5635223.
   PubMed Web of Science ®Google Scholar
• Ratjen F, Bell SC, Rowe SM, et al. Cystic fibrosis. Nat Rev Dis Primers. 2015 May;14(1):15010. PubMed PMID: 27189798.
   PubMed Web of Science ®Google Scholar
• Burney TJ, Davies JC. Gene therapy for the treatment of cystic fibrosis. Appl Clin Genet. 2012;5:29–36. PubMed PMID: 23776378; PubMed Central PMCID: PMCPMC3681190.
   PubMedGoogle Scholar
• Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994 Sep;8(1):42–51. PubMed PMID: 7527271.
   PubMed Web of Science ®Google Scholar
• Guggino WB, Cebotaru L. Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opin Biol Ther. 2017 Oct;17(10):1265–1273. PubMed PMID: 28657358; PubMed Central PMCID: PMCPMC5858933.
   PubMed Web of Science ®Google Scholar
• Cooney AL, McCray PB Jr., Sinn PL. Cystic fibrosis gene therapy: looking back, looking forward. Genes (Basel). 2018 Nov 7;9(11):538. PubMed PMID: 30405068; PubMed Central PMCID: PMCPMC6266271.
   PubMed Web of Science ®Google Scholar
• Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990;63:827–834.
   PubMed Web of Science ®Google Scholar
• Denning GM, Anderson MP, Amara JF, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992;358:761–764.
   PubMed Web of Science ®Google Scholar
• Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the ∆F508 cystic fibrosis mutation. Nature. 1991;354:526–528.
   PubMed Web of Science ®Google Scholar
• Lukacs GL, Chang X-B, Bear C, et al. The ∆F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. JBiolChem. 1993;1993(268):21592–21598.
   Google Scholar
• Kopito RR, Ron D. Conformational disease [Congresses]. Nat Cell Biol. 2000 Nov;2(11):E207–9. PubMed PMID: 11056553.
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M. CFTR modulators: shedding light on precision medicine for cystic fibrosis. Front Pharmacol. 2016;7:275. PubMed PMID: 27656143; PubMed Central PMCID: PMCPMC5011145.
   PubMed Web of Science ®Google Scholar
• Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med. 2012 Feb;18(2):81–91. PubMed PMID: 22138491; PubMed Central PMCID: PMCPMC3643519.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med. 2013 Jul 1;3(7). DOI:10.1101/cshperspect.a009761. PubMed PMID: 23818513; PubMed Central PMCID: PMCPMC3685879.
   PubMed Web of Science ®Google Scholar
• Kim Chiaw P, Eckford PD, Bear CE. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Essays Biochem. 2011 Sep 7;50(1):233–248. PubMed PMID: 21967060.
   PubMed Web of Science ®Google Scholar
• Ong T, Ramsey BW. New therapeutic approaches to modulate and correct cystic fibrosis transmembrane conductance regulator. Pediatr Clin North Am. 2016 Aug;63(4):751–764. PubMed PMID: 27469186; PubMed Central PMCID: PMCPMC5478192.
   PubMed Web of Science ®Google Scholar
• Barry PJ, Jones AM. New and emerging treatments for cystic fibrosis. Drugs. 2015 Jul;75(11):1165–1175. PubMed PMID: 26091951.
   PubMed Web of Science ®Google Scholar
• Hanrahan JW, Sampson HM, Thomas DY. Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci. 2013 Feb;34(2):119–125. PubMed PMID: 23380248.
   PubMed Web of Science ®Google Scholar
• Hanrahan JW, Matthes E, Carlile G, et al. Corrector combination therapies for F508del-CFTR. Curr Opin Pharmacol. 2017 Jun;34:105–111. PubMed PMID: 29080476.
   PubMed Web of Science ®Google Scholar
• Clancy JP. Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol. 2018 Nov;53(S3):S4–S11. PubMed PMID: 30289627.
   PubMed Web of Science ®Google Scholar
• Burgener EB, Moss RB. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Curr Opin Pediatr. 2018 Jun;30(3):372–377. PubMed PMID: 29538046.
   PubMed Web of Science ®Google Scholar
• Li H, Pesce E, Sheppard DN, et al. Therapeutic approaches to CFTR dysfunction: from discovery to drug development. J Cystic Fibrosis. 2018 Mar;17(2S):S14–S21. PubMed PMID: 28916430.
   PubMed Web of Science ®Google Scholar
• Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol. 2001;281:C1734–C1742.
   PubMed Web of Science ®Google Scholar
• Maitra R, Sivashanmugam P, Warner K. A rapid membrane potential assay to monitor CFTR function and inhibition. J Biomol Screen. 2013 Oct;18(9):1132–1137. PubMed PMID: WOS:000324760300018; English.
   PubMedGoogle Scholar
• Mutyam V, Du M, Xue X, et al. Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations. Am J Respir Crit Care Med. 2016 Nov 1;194(9):1092–1103. PubMed PMID: 27104944; PubMed Central PMCID: PMCPMC5114449.
   PubMed Web of Science ®Google Scholar
• Howard M, DuVall MD, Devor DC, et al. Epitope tagging permits cell surface detection of functional CFTR. Am J Physiol Cell Physiol. 1995;269:C1565–C1576.
   Web of Science ®Google Scholar
• Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med. 2014 Jul 23;6(246):246ra97. PubMed PMID: 25101887.
   PubMed Web of Science ®Google Scholar
• Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem Eur J Chem Biol. 2007 Jun 18;8(9):1012–1020. PubMed PMID: 17497613.
   PubMed Web of Science ®Google Scholar
• Phuan PW, Veit G, Tan J, et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields DeltaF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014 Jul;86(1):42–51. PubMed PMID: 24737137; PubMed Central PMCID: PMCPMC4054004.
   PubMed Web of Science ®Google Scholar
• Dekkers JF, Berkers G, Kruisselbrink E, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016 Jun 22;8(344):344ra84. PubMed PMID: 27334259.
   PubMed Web of Science ®Google Scholar
• Guimbellot JS, Leach JM, Chaudhry IG, et al. Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight. 2017 Nov 16;2(22):95734. PubMed PMID: 29202459; PubMed Central PMCID: PMCPMC5752372.
   PubMed Web of Science ®Google Scholar
• Box GEP, Draper NR. Empirical model-building and response surfaces. New York: John Wiley and Sons, Inc; 1987.
   Google Scholar
• Matthes E, Goepp J, Martini C, et al. Variable responses to CFTR correctors in vitro: estimating the design effect in precision medicine. Front Pharmacol. 2018;9. DOI:10.3389/fphar.2018.01490.
   PubMed Web of Science ®Google Scholar
• Pranke IM, Hatton A, Simonin J, et al. Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. Sci Rep. 2017 Aug 7;7(1):7375. PubMed PMID: 28785019; PubMed Central PMCID: PMCPMC5547155.
   PubMed Web of Science ®Google Scholar
• Farmen SL, Karp PH, Ng P, et al. Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR [Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov’t]. Am J Physiol Lung Cell Mol Physiol. 2005 Dec;289(6):L1123–30. PubMed PMID: 16085675.
   PubMed Web of Science ®Google Scholar
• Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t]. PLoS Biol. 2009 Jul;7(7):e1000155. PubMed PMID: 19621064; PubMed Central PMCID: PMC2705187.
   PubMed Web of Science ®Google Scholar
• Sampson HM, Robert R, Liao J, et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol. 2011 Feb 25;18(2):231–242. PubMed PMID: 21338920.
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843–18848. PubMed PMID: 21976485; PubMed Central PMCID: PMC3219147.
   PubMed Web of Science ®Google Scholar
• Hudson RP, Dawson JE, Chong PA, et al. Direct binding of the corrector VX-809 to human CFTR NBD1: evidence of an allosteric coupling between the binding site and the NBD1: CL4Interface. Mol Pharmacol. 2017 Aug 1;92(2):124–135. PubMed PMID: WOS:000407023300003; English
   PubMed Web of Science ®Google Scholar
• Carlile GW, Yang Q, Matthes E, et al. A novel triple combination of pharmacological chaperones improves F508del-CFTR correction. Sci Rep. 2018 Jul 30;8(1):11404. PubMed PMID: 30061653; PubMed Central PMCID: PMCPMC6065411.
   PubMed Web of Science ®Google Scholar
• Sabirzhanova I, Lopes Pacheco M, Rapino D, et al. Rescuing trafficking mutants of the ATP-binding cassette protein, ABCA4, with small molecule correctors as a treatment for stargardt eye disease. J Biol Chem. 2015 Aug 7;290(32):19743–19755. PubMed PMID: 26092729; PubMed Central PMCID: PMCPMC4528136.
   PubMed Web of Science ®Google Scholar
• Miller JP, Drew L, Green O, et al. WS13.5 CFTR amplifiers are mutation-agnostic modulators that increase CFTR protein levels and complement other CF therapeutic modalities. J Cyst Fib. 2016;15:s22.
   Google Scholar
• Chung WJ, Goeckeler-Fried JL, Havasi V, et al. Increasing the endoplasmic reticulum pool of the F508del allele of the cystic fibrosis transmembrane conductance regulator leads to greater folding correction by small molecule therapeutics. PLoS One. 2016;11(10):e0163615. PubMed PMID: 27732613; PubMed Central PMCID: PMCPMC5061379 alter our adherence to PLOS ONE policies on sharing data and materials..
   PubMed Web of Science ®Google Scholar
• Molinski SV, Ahmadi S, Ip W, et al. Orkambi(R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. EMBO Mol Med. 2017 Sep;9(9):1224–1243. PubMed PMID: 28667089; PubMed Central PMCID: PMCPMC5582412.
   PubMed Web of Science ®Google Scholar
• Ou WJ, Bergeron JJ, Li Y, et al. Conformational changes induced in the endoplasmic reticulum luminal domain of calnexin by Mg-ATP and Ca2+. J Biol Chem. 1995 Jul 28;270(30):18051–18059. PubMed PMID: 7629114; eng
   PubMed Web of Science ®Google Scholar
• Maattanen P, Gehring K, Bergeron JJ, et al. Protein quality control in the ER: the recognition of misfolded proteins. Semin Cell Dev Biol. 2010 Jul;21(5):500–511. PubMed PMID: 20347046.
   PubMed Web of Science ®Google Scholar
• Noel S, Wilke M, Bot AG, et al. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther. 2008 Jun;325(3):1016–1023. PubMed PMID: 18309088.
   PubMed Web of Science ®Google Scholar
• Loo MA, Jensen TJ, Cui L, et al. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. Embo J. 1998 Dec 1;17(23):6879–6887. PubMed PMID: 9843494; PubMed Central PMCID: PMCPMC1171036.
   PubMed Web of Science ®Google Scholar
• Grove DE, Rosser MF, Watkins RL, et al. Analysis of CFTR folding and degradation in transiently transfected cells. Methods Mol Biol. 2011;741:219–232. PubMed PMID: 21594788; PubMed Central PMCID: PMCPMC4460993.
   PubMedGoogle Scholar
• Meacham GC, Lu Z, King S, et al. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. Embo J. 1999 Mar 15;18(6):1492–1505. PubMed PMID: 10075921; PubMed Central PMCID: PMCPMC1171238.
   PubMed Web of Science ®Google Scholar
• Coppinger JA, Hutt DM, Razvi A, et al. A chaperone trap contributes to the onset of cystic fibrosis. PLoS One. 2012;7(5):e37682. PubMed PMID: 22701530; PubMed Central PMCID: PMCPMC3365120.
   PubMed Web of Science ®Google Scholar
• Farinha CM, Nogueira P, Mendes F, et al. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J. 2002 Sep 15;366(Pt 3):797–806. PubMed PMID: 12069690; PubMed Central PMCID: PMCPMC1222832.
   PubMed Web of Science ®Google Scholar
• Wang X, Venable J, LaPointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell. 2006 Nov 17;127(4):803–815. S0092-8674(06)01378-X [pii]. PubMed PMID: 17110338; eng.
   PubMed Web of Science ®Google Scholar
• Meacham GC, Patterson C, Zhang W, et al. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol. 2001 Jan;3(1):100–105. PubMed PMID: 11146634.
   PubMed Web of Science ®Google Scholar
• Morito D, Hirao K, Oda Y, et al. Gp78 cooperates with RMA1 in endoplasmic reticulum-associated degradation of CFTRDeltaF508. Mol Biol Cell. 2008 Apr;19(4):1328–1336. PubMed PMID: 18216283; PubMed Central PMCID: PMCPMC2291415.
   PubMed Web of Science ®Google Scholar
• Younger JM, Chen L, Ren HY, et al. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell. 2006 Aug 11;126(3):571–582. PubMed PMID: 16901789.
   PubMed Web of Science ®Google Scholar
• Saxena A, Banasavadi-Siddegowda YK, Fan Y, et al. Human heat shock protein 105/110 kDa (Hsp105/110) regulates biogenesis and quality control of misfolded cystic fibrosis transmembrane conductance regulator at multiple levels. J Biol Chem. 2012 Jun 1;287(23):19158–19170. PubMed PMID: 22505710; PubMed Central PMCID: PMCPMC3365948.
   PubMed Web of Science ®Google Scholar
• Schmidt BZ, Watts RJ, Aridor M, et al. Cysteine string protein promotes proteasomal degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) by increasing its interaction with the C terminus of Hsp70-interacting protein and promoting CFTR ubiquitylation. J Biol Chem. 2009 Feb 13;284(7):4168–4178. PubMed PMID: 19098309; PubMed Central PMCID: PMCPMC2640980.
   PubMed Web of Science ®Google Scholar
• Alberti S, Bohse K, Arndt V, et al. The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator. Mol Biol Cell. 2004 Sep;15(9):4003–4010. PubMed PMID: 15215316; PubMed Central PMCID: PMCPMC515335.
   PubMed Web of Science ®Google Scholar
• Arndt V, Daniel C, Nastainczyk W, et al. BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. Mol Biol Cell. 2005 Dec;16(12):5891–5900. PubMed PMID: 16207813; PubMed Central PMCID: PMCPMC1289430.
   PubMed Web of Science ®Google Scholar
• Dai Q, Qian SB, Li HH, et al. Regulation of the cytoplasmic quality control protein degradation pathway by BAG2. J Biol Chem. 2005 Nov 18;280(46):38673–38681. PubMed PMID: 16169850.
   PubMed Web of Science ®Google Scholar
• Sopha P, Kadokura H, Yamamoto YH, et al. A novel mammalian ER-located J-protein, DNAJB14, can accelerate ERAD of misfolded membrane proteins. Cell Struct Funct. 2012;37(2):177–187. PubMed PMID: 23018488.
   PubMed Web of Science ®Google Scholar
• Yamamoto YH, Kimura T, Momohara S, et al. A novel ER J-protein DNAJB12 accelerates ER-associated degradation of membrane proteins including CFTR. Cell Struct Funct. 2010;35(2):107–116. PubMed PMID: 21150129.
   PubMed Web of Science ®Google Scholar
• Seo JH, Park JH, Lee EJ, et al. ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation. Nat Commun. 2016 Oct;6(7):12882. PubMed PMID: 27708256; PubMed Central PMCID: PMCPMC5059642.
   PubMed Web of Science ®Google Scholar
• Grove DE, Rosser MF, Ren HY, et al. Mechanisms for rescue of correctable folding defects in CFTRDelta F508. Mol Biol Cell. 2009 Sep;20(18):4059–4069. PubMed PMID: 19625452; PubMed Central PMCID: PMCPMC2743624.
   PubMed Web of Science ®Google Scholar
• Tomati V, Sondo E, Armirotti A, et al. Genetic inhibition of the ubiquitin ligase Rnf5 attenuates phenotypes associated to F508del cystic fibrosis mutation. Sci Rep. 2015 Jul;17(5):12138. PubMed PMID: 26183966; PubMed Central PMCID: PMCPMC4505316.
   PubMed Web of Science ®Google Scholar
• Landre V, Rotblat B, Melino S, et al. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities. Oncotarget. 2014 Sep 30;5(18):7988–8013. PubMed PMID: 25237759; PubMed Central PMCID: PMCPMC4226663.
   PubMedGoogle Scholar
• Sondo E, Falchi F, Caci E, et al. Pharmacological inhibition of the ubiquitin ligase RNF5 rescues F508del-CFTR in cystic fibrosis airway epithelia. Cell Chem Biol. 2018 Jul 19;25(7):891–905 e8. PubMed PMID: 29754957.
   PubMed Web of Science ®Google Scholar
• Liang X, Da Paula AC, Bozoky Z, et al. Phosphorylation-dependent 14-3-3 protein interactions regulate CFTR biogenesis. Mol Biol Cell. 2012 Mar;23(6):996–1009. PubMed PMID: 22278744; PubMed Central PMCID: PMC3302758.
   PubMed Web of Science ®Google Scholar
• Stevers LM, Lam CV, Leysen SF, et al. Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR. Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1152–61. PubMed PMID: 26888287; PubMed Central PMCID: PMCPMC4780605.
   PubMed Web of Science ®Google Scholar
• Fukuda R, Okiyoneda T. Peripheral protein quality control as a novel drug target for CFTR stabilizer. Front Pharmacol. 2018;9:1100. PubMed PMID: 30319426; PubMed Central PMCID: PMCPMC6170605.
   PubMed Web of Science ®Google Scholar
• Okiyoneda T, Barriere H, Bagdany M, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science. 2010 Aug 13;329(5993):805–810. PubMed PMID: 20595578; PubMed Central PMCID: PMCPMC5026491.
   PubMed Web of Science ®Google Scholar
• Bagdany M, Veit G, Fukuda R, et al. Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell. Nat Commun. 2017 Aug 30;8(1):398. PubMed PMID: 28855508; PubMed Central PMCID: PMCPMC5577305.
   PubMed Web of Science ®Google Scholar
• Park HJ, Mylvaganum M, McPherson A, et al. A soluble sulfogalactosyl ceramide mimic promotes Delta F508 CFTR escape from endoplasmic reticulum associated degradation. Chem Biol. 2009 Apr 24;16(4):461–470. PubMed PMID: 19389632; PubMed Central PMCID: PMCPMC4375101.
   PubMedGoogle Scholar
• Cho HJ, Gee HY, Baek KH, et al. A small molecule that binds to an ATPase domain of Hsc70 promotes membrane trafficking of mutant cystic fibrosis transmembrane conductance regulator. J Am Chem Soc. 2011 Dec 21;133(50):20267–20276. PubMed PMID: 22074182.
   PubMed Web of Science ®Google Scholar
• Luciani A, Villella VR, Esposito S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol. 2010 Sep;12(9):863–875. PubMed PMID: 20711182.
   PubMed Web of Science ®Google Scholar
• Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998 Dec 28;143(7):1883–1898. PubMed PMID: 9864362; PubMed Central PMCID: PMCPMC2175217.
   PubMed Web of Science ®Google Scholar
• Esposito S, Tosco A, Villella VR, et al. Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis. Mol Cell Pediatr. 2016 Dec;3(1):13. PubMed PMID: 26976279; PubMed Central PMCID: PMCPMC4791443.
   PubMedGoogle Scholar
• De Stefano D, Villella VR, Esposito S, et al. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy. 2014;10(11):2053–2074. PubMed PMID: 25350163; PubMed Central PMCID: PMCPMC4502695.
   PubMed Web of Science ®Google Scholar
• Tosco A, De Gregorio F, Esposito S, et al. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ. 2016 Aug;23(8):1380–1393. PubMed PMID: 27035618; PubMed Central PMCID: PMCPMC4947669.
   PubMed Web of Science ®Google Scholar
• Vu CB, Bridges RJ, Pena-Rasgado C, et al. Fatty acid cysteamine conjugates as novel and potent autophagy activators that enhance the correction of misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). J Med Chem. 2017 Jan 12;60(1):458–473. PubMed PMID: 27976892.
   PubMed Web of Science ®Google Scholar
• King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151–178. PubMed PMID: 27450734.
   PubMed Web of Science ®Google Scholar
• Chaudhary K, Shinde R, Liu H, et al. Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy. J Iimmunol. 2015 Jun 15;194(12):5713–5724. PubMed PMID: 25980011; PubMed Central PMCID: PMCPMC4458436.
   PubMed Web of Science ®Google Scholar
• Romani L, Oikonomou V, Moretti S, et al. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. 2017 May;23(5):590–600. PubMed PMID: 28394330; PubMed Central PMCID: PMCPMC5420451.
   PubMed Web of Science ®Google Scholar
• Tomati V, Caci E, Ferrera L, et al. Thymosin alpha-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia. JCI Insight. 2018 Feb 8;3(3). PubMed PMID: 29415893; PubMed Central PMCID: PMCPMC5821210. DOI:10.1172/jci.insight.98699.
   PubMed Web of Science ®Google Scholar
• Matthes E, Hanrahan JW, Cantin AM. F508del-CFTR is not corrected by thymosin alpha1. Nat Med. 2018 Jul;24(7):890–891. PubMed PMID: 29942095.
   PubMed Web of Science ®Google Scholar
• Romani L, Stincardini C, Giovagnoli S, et al. Reply to ‘F508del-CFTR is not corrected by thymosin alpha1ʹ. Nat Med. 2018 Jul;24(7):891–893. PubMed PMID: 29942090.
   PubMed Web of Science ®Google Scholar
• Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect [Comparative StudyResearch Support, Non-U.S. Gov’t]. Mol Pharmacol. 2008 Feb;73(2):478–489. PubMed PMID: 17975008.
   PubMed Web of Science ®Google Scholar
• Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010 Jan;6(1):25–33. PubMed PMID: 19966789; PubMed Central PMCID: PMC2901172.
   PubMed Web of Science ®Google Scholar
• Carlile GW, Robert R, Goepp J, et al. Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. J Cystic Fibrosis. 2015 Jan;14(1):16–25. PubMed PMID: 24974227.
   PubMed Web of Science ®Google Scholar
• Robert R, Carlile GW, Liao J, et al. Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine [Research Support, Non-U.S. Gov’t]. Mol Pharmacol. 2010 Jun;77(6):922–930. PubMed PMID: 20200141.
   PubMed Web of Science ®Google Scholar
• Trzcinska-Daneluti AM, Nguyen L, Jiang C, et al. Use of kinase inhibitors to correct ∆F508-CFTR function. MolCellProteomics. 2012;11:745–757.
   Web of Science ®Google Scholar
• Carlile GW, Keyzers RA, Teske KA, et al. Correction of F508del-CFTR trafficking by the sponge alkaloid latonduine is modulated by interaction with PARP. Chem Biol. 2012 Oct 26;19(10):1288–1299. PubMed PMID: 23102222.
   PubMed Web of Science ®Google Scholar
• Zhang D, Ciciriello F, Anjos SM, et al. Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells. Front Pharmacol. 2012;3:176. PubMed PMID: 23060796; PubMed Central PMCID: PMC3463858.
   PubMed Web of Science ®Google Scholar
• Moniz S, Sousa M, Moraes BJ, et al. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem Biol. 2013 Feb 15;8(2):432–442. PubMed PMID: 23148778.
   PubMed Web of Science ®Google Scholar
• Sondo E, Tomati V, Caci E, et al. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol. 2011 Oct;301(4):C872–85. PubMed PMID: 21753184; PubMed Central PMCID: PMCPMC3512166.
   PubMed Web of Science ®Google Scholar
• Bergougnoux A, Petit A, Knabe L, et al. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in cystic fibrosis. Int J Biochem Cell Biol. 2017 Jul;88:124–132. . PubMed PMID: 28478266.
   PubMed Web of Science ®Google Scholar
• Anonymous. Withdrawl of glafenine. Lancet. 1992;339:357.
   Google Scholar
• Chiu AMMJ, Loganathan SK, Alka K, et al. High throughput assay identifies glafenine as a corrector for the folding defect in corneal dystrophy-causing mutants of SLC4A11. Invest Ophthalmol Vis Sci. 2015;56:7739–7753.
   PubMed Web of Science ®Google Scholar
• Alka K, Casey J. Molecular phenotype of SLC4A11 missense mutants: setting the stage for personalized medicine in corneal dystrophies. Hum Mutat. 2018;39:1002(Jan 11).
   Google Scholar
• Perkins LA, Fisher GW, Naganbabu M, et al. High-content surface and total expression siRNA kinase library screen with VX-809 treatment reveals kinase targets that enhance F508del-CFTR rescue. Mol Pharm. 2018 Mar 5;15(3):759–767. PubMed PMID: 29384380; PubMed Central PMCID: PMCPMC5844356.
   PubMed Web of Science ®Google Scholar
• Carlile GW, Robert R, Matthes E, et al. Latonduine analogs restore F508del-cystic fibrosis transmembrane conductance regulator trafficking through the modulation of poly-ADP ribose polymerase 3 and poly-ADP ribose polymerase 16 activity. Mol Pharmacol. 2016 Aug;90(2):65–79. PubMed PMID: 27193581.
   PubMed Web of Science ®Google Scholar
• Zhang S, Malmersjo S, Li J, et al. Distinct role of the N-terminal tail of the Na,K-ATPase catalytic subunit as a signal transducer. J Biol Chem. 2006 Aug 4;281(31):21954–21962. PubMed PMID: 16723354.
   PubMed Web of Science ®Google Scholar
• Li J, Zelenin S, Aperia A, et al. Low doses of ouabain protect from serum deprivation-triggered apoptosis and stimulate kidney cell proliferation via activation of NF-kappaB. J Am Soc Nephrol. 2006 Jul;17(7):1848–1857. PubMed PMID: 16707566.
   PubMed Web of Science ®Google Scholar
• Srivastava M, Eidelman O, Zhang J, et al. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci U S A. 2004 May 18;101(20):7693–7698. PubMed PMID: 15136726; PubMed Central PMCID: PMCPMC419668.
   PubMed Web of Science ®Google Scholar
• Favia M, Guerra L, Fanelli T, et al. Na+/H+ exchanger regulatory factor 1 overexpression-dependent increase of cytoskeleton organization is fundamental in the rescue of F508del cystic fibrosis transmembrane conductance regulator in human airway CFBE41o- cells. Mol Biol Cell. 2010 Jan 1;21(1):73–86. PubMed PMID: 19889841; PubMed Central PMCID: PMC2801722.
   PubMed Web of Science ®Google Scholar
• White NM, Jiang D, Burgess JD, et al. Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007 Feb;292(2):L476–86. PubMed PMID: 17085523.
   PubMed Web of Science ®Google Scholar
• Fang D, West RH, Manson ME, et al. Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis. Respir Res. 2010;11:61. PubMed PMID: 20487541; PubMed Central PMCID: PMC2880018.
   PubMed Web of Science ®Google Scholar
• Gentzsch M, Choudhury A, Chang XB, et al. Misassembled mutant deltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J Cell Sci. 2007;120:447–455.
   PubMed Web of Science ®Google Scholar
• Abu-Arish A, Pandzic E, Goepp J, et al. Cholesterol modulates CFTR confinement in the plasma membrane of primary epithelial cells. Biophys J. 2015;109(1):85–94.
   PubMed Web of Science ®Google Scholar
• Freedman SD, Katz MH, Parker EM, et al. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice. ProcNatlAcadSciUSA. 1999;1999(96):13995–14000.
   Web of Science ®Google Scholar
• Guilbault C, Wojewodka G, Saeed Z, et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol. 2009;41(1):100–106. PubMed PMID: Medline:19059886; English.
   PubMed Web of Science ®Google Scholar
• Grassmé H, Jendrossek V, Riehle A, et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med. 2003;9:322–330.
   PubMed Web of Science ®Google Scholar
• Laviad EL, Kelly S, Merrill AH Jr. et al. Modulation of ceramide synthase activity via dimerization. J Biol Chem. 2012 Jun 15;287(25):21025–21033. . PubMed PMID: 22539345; PubMed Central PMCID: PMCPMC3375526.
   PubMed Web of Science ®Google Scholar
• Guilbault C, De Sanctis JB, Wojewodka G, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol. 2008 Jan;38(1):47–56. PubMed PMID: 17656682.
   PubMed Web of Science ®Google Scholar
• Wojewodka G, De Sanctis JB, Radzioch D. Ceramide in cystic fibrosis: a potential new target for therapeutic intervention. J Lipids. 2011;674968. DOI:10.1155/2011/674968. PubMed PMID: 21490807; PubMed Central PMCID: PMC3066841.
   PubMedGoogle Scholar
• Garic D, De Sanctis JB, Wojewodka G, et al. Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside. J Mol Med (Berl). 2017 Oct;95(10):1053–1064. PubMed PMID: 28695226.
   PubMed Web of Science ®Google Scholar
• Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science. 2008;322:590–594.
   PubMed Web of Science ®Google Scholar
• Schroeder BC, Cheng T, Jan YN, et al. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell. 2008 Sep 19;134(6):1019–1029. PubMed PMID: 18805094; PubMed Central PMCID: PMCPMC2651354.
   PubMed Web of Science ®Google Scholar
• Yang YD, Cho H, Koo JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008 Oct 30;455(7217):1210–1215. PubMed PMID: 18724360.
   PubMed Web of Science ®Google Scholar
• Galietta LJ, Pagesy P, Folli C, et al. IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro. JImmunol. 2002;168:839–845.
   PubMed Web of Science ®Google Scholar
• Huang F, Zhang H, Wu M, et al. Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16354–16359. PubMed PMID: 22988107; PubMed Central PMCID: PMCPMC3479591.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulou P, Riederer B, Duerr J, et al. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest. 2012 Oct;122(10):3629–3634. PubMed PMID: 22945630; PubMed Central PMCID: PMCPMC3461899.
   PubMed Web of Science ®Google Scholar
• Sun L, Rommens JM, Corvol H, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet. 2012 May;44(5):562–569. PubMed PMID: 22466613; PubMed Central PMCID: PMCPMC3371103.
   PubMed Web of Science ®Google Scholar
• Strug LJ, Gonska T, He G, et al. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum Mol Genet. 2016 Oct 15;25(20):4590–4600. PubMed PMID: 28171547; PubMed Central PMCID: PMCPMC5886039.
   PubMed Web of Science ®Google Scholar
• Bertrand CA, Zhang R, Pilewski JM, et al. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol. 2009;133:421–438.
   PubMed Web of Science ®Google Scholar
• Bertrand CA, Mitra S, Mishra SK, et al. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9. Am J Physiol Lung Cell Mol Physiol. 2017 Jun 1;312(6):L912–L925. PubMed PMID: 28360110; PubMed Central PMCID: PMCPMC5495941.
   PubMed Web of Science ®Google Scholar
• Li H, Salomon JJ, Sheppard DN, et al. Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. Curr Opin Pharmacol. 2017 Jun;34:91–97. PubMed PMID: 29065356.
   PubMed Web of Science ®Google Scholar
• Joo NS, Jeong JH, Cho HJ, et al. Marked increases in mucociliary clearance produced by synergistic secretory agonists or inhibition of the epithelial sodium channel. Sci Rep-Uk. 2016 Nov;10:6. PubMed PMID: WOS:000388090100001; English.
   Google Scholar
• Astrand ABM, Hemmerling M, Root J, et al. Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition. Am J Physiol-Lung C. 2015 Jan 1;308(1):L22–L32. PubMed PMID: WOS:000347230700003; English
   PubMed Web of Science ®Google Scholar
• Hirsh AJ, Sabater JR, Zamurs A, et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther. 2004 Dec;311(3):929–938. PubMed PMID: WOS:000225198200009; English.
   PubMed Web of Science ®Google Scholar
• Knowles MR, Church NL, Waltner WE, et al. A pilot-study of aerosolized amiloride for the treatment of lung-disease in cystic-fibrosis. New Engl J Med. 1990 Apr 26;322(17):1189–1194. PubMed PMID: WOS:A1990DA35100004; English
   PubMed Web of Science ®Google Scholar
• O’Riordan TG, Donn KH, Hodsman P, et al. Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J Aerosol Med Pulm D. 2014 Jun;27(3):200–208. PubMed PMID: WOS:000337165400006; English.
   PubMed Web of Science ®Google Scholar
• Coote KJ, Paisley D, Czarnecki S, et al. NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia. Br J Pharmacol. 2015 Jun;172(11):2814–2826. PubMed PMID: 25573195; PubMed Central PMCID: PMCPMC4439877.
   PubMed Web of Science ®Google Scholar
• Terryah ST, Fellner RC, Ahmad S, et al. Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease. Am J Physiol-Lung C. 2018 Jan;314(1):L192–L205. PubMed PMID: WOS:000426199600004; English.
   PubMed Web of Science ®Google Scholar
• Scott DW, Walker MP, Sesma J, et al. SPX-101 is a novel epithelial sodium channel-targeted therapeutic for cystic fibrosis that restores mucus transport. Am J Resp Crit Care. 2017 Sep 15;196(6):734–744. PubMed PMID: WOS:000410857700016; English
   PubMed Web of Science ®Google Scholar
• Rollins BM, Garcia-Caballero A, Stutts MJ, et al. SPLUNC1 expression reduces surface levels of the epithelial sodium channel (ENaC) in Xenopus laevis oocytes. Channels. 2010 Jul-Aug;4(4):255–259. PubMed PMID: WOS:000284336200003; English.
   PubMed Web of Science ®Google Scholar
• Hobbs CA, Blanchard MG, Alijevic O, et al. Identification of the SPLUNC1 ENaC- inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures. Am J Physiol-Lung C. 2013 Dec;305(12):L990–L1001. PubMed PMID: WOS:000328750900010; English.
   PubMed Web of Science ®Google Scholar
• Moore PJ, Tarran R. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease. Expert Opin Ther Targets. 2018 Jul 20. DOI:10.1080/14728222.2018.1501361. PubMed PMID: 30028216.
   PubMed Web of Science ®Google Scholar
• Tagalakis AD, Munye MM, Ivanova R, et al. Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung. Thorax. 2018;73:847–856. in press.
   PubMed Web of Science ®Google Scholar
• Di Gioia S, Trapani A, Castellani S, et al. Nanocomplexes for gene therapy of respiratory diseases: targeting and overcoming the mucus barrier. Pulm Pharmacol Ther. 2015 Oct;34:8–24. PubMed PMID: WOS:000363353100002; English.
   PubMed Web of Science ®Google Scholar
• Manunta MDI, Tagalakis AD, Attwood M, et al. Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis. Sci Rep. 2017 Apr 6;7(1):700. PubMed PMID: 28386087; PubMed Central PMCID: PMCPMC5428798.
   PubMed Web of Science ®Google Scholar
• Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012 Mar 1;11(3):191–200. PubMed PMID: 22378269.
   PubMed Web of Science ®Google Scholar